1. 105 HIGH RESPONSE RATE FOR AZACITIDINE-LENALIDOMIDE (VI-LEN) COMBINATION IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - VILEN-01 PROTOCOL UPDATE. (April 2015) Authors: Mittelman, M.; Filanovsky, K.; Ofran, Y.; Raanani, P.; Braester, A.; Goldshmidt, N.; Kirgner, I.; Herishanu, Y.; Perry, C.; Oster, H.S. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of Combination Ultra Q10 and L-Carnitine on the Clinical Course and Mitochondrial Function of Patients with Myelodysplastic Syndrome (MDS). (April 2017) Authors: Filanovsky, K.; Haran, M.; Mirkin, V.; Shvetz, O.; Stanevsky, A.; Sigler, E.; Braester, A.; Zaltsman, Y.; Gross, A.; Shvidel, L. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The Oral Iron Chelator Deferiprone Decreases Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS). (April 2017) Authors: Merkel, D.; Soffer, S.; Filanovsky, K.; Fibach, E.; Dana, M.; Mittelman, M.; Nagler, A.; Rachmilewitz, E.A. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗